Eli Lilly & Co.'s Taltz (ixekizumab) aced its second Phase III study in ankylosing spondylitis, putting it on track for a US FDA filing later this year, which will set the interleukin-17A (IL-17A) inhibitor on a level playing field with its biggest rival – Novartis AG's Cosentyx (secukinumab).
Novartis has been very clear about its intention to turn ankylosing spondylitis (AS) into one of three blockbuster indications for...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)